Two of the most prescribed GLP-1 drugs for type 2 diabetes go head-to-head: Ozempic (semaglutide) from Novo Nordisk and Mounjaro (tirzepatide) from Eli Lilly. The good news: both work. The interesting news: Mounjaro produced larger A1C and weight-loss results in the only direct head-to-head trial. Here’s the full comparison.
Mechanism: Single vs. Dual Incretin Action
Ozempic activates one receptor — GLP-1. Mounjaro activates two — both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The GIP receptor adds another insulin-releasing pathway, which appears to amplify both glucose control and weight loss compared to GLP-1 activation alone. This dual-action mechanism is why Mounjaro is sometimes called a “twincretin” agonist.
Head-to-Head Trial: SURPASS-2
The SURPASS-2 trial (published in NEJM, 2021) directly compared tirzepatide (5, 10, 15 mg) to semaglutide 1 mg in 1,879 type 2 diabetes patients over 40 weeks. Results:
| Outcome | Semaglutide 1 mg | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg |
|---|---|---|---|---|
| A1C reduction | -1.86% | -2.01% | -2.24% | -2.30% |
| Weight loss (avg) | -13.0 lbs | -16.7 lbs | -21.6 lbs | -25.4 lbs |
| % reaching A1C <5.7% | 19% | 27% | 40% | 46% |
Side Effects: Both Drugs Similar
Nausea, diarrhea, constipation, and reduced appetite are common during dose titration for both drugs. The frequency and severity is comparable in head-to-head data. Most patients adapt within 4–8 weeks at each dose level.
For a complete safety profile, see our Ozempic side effects guide (most apply to Mounjaro too).
Cost Comparison
| Drug | Retail price (1 month) | With insurance | Savings card eligibility |
|---|---|---|---|
| Ozempic | $900 – $1,200 | $25 – $100 | Yes (Novo Nordisk savings card) |
| Mounjaro | $1,000 – $1,200 | $25 – $200 | Yes (Lilly savings card) |
When to Choose Which
Mounjaro is generally preferred when:
- Weight loss is a primary treatment goal alongside glycemia
- A1C is far from target and maximum effect is needed
- You’ve tried a GLP-1 agonist and want a more potent option
Ozempic may be preferred when:
- Cardiovascular risk reduction is a primary goal (more long-term CV outcome data)
- Insurance coverage favors it on formulary
- You’ve been stable on it and don’t need to switch
Both drugs are excellent. The choice often comes down to insurance formulary, individual response, and which manufacturer’s savings card you can use. Talk to your doctor.
Sources & Further Reading
- SURPASS-2 Trial (Tirzepatide vs Semaglutide) — NEJM
- FDA Prescribing Information — Ozempic
- FDA Prescribing Information — Mounjaro
- ADA Standards of Care 2024
